title: Effective in vivo purging with rituximab and autologous peripheral blood stem cell transplantation in a woman with CD5 positive primary cutaneous diffuse large B-cell lymphoma.
abstract: Generalized subcutaneous tumors developed without any other sites of the disease in a Japanese woman. Skin biopsy revealed CD5(+) and CD20(+) atypical diffuse large cells infiltrating subcutaneous tissues. The diagnosis was CD5(+) primary cutaneous diffuse large B-cell lymphoma. Tumor-specific PCR showed the existence of malignant cells in the peripheral blood and bone marrow. After three cycles of chemotherapy, she was remained in partial remission. Peripheral blood stem cells (PBSC) were harvested after the fourth cycles of chemotherapy combined with rituximab for in vivo purging. The contamination of tumor cells in PBSC was negative with PCR. She then underwent autologous peripheral blood stem cell transplantation using purged PBSC and has remained in complete remission for the past 24 month.
authors.affiliation: Department of Medicine II, Hokkaido University Graduated School of Medicine, Sapporo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Goto
authors.forename: M
authors.initials: M
authors.lastname: Nishio
authors.forename: T
authors.initials: T
authors.lastname: Endo
authors.forename: N
authors.initials: N
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Koizumi
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
authors.forename: T
authors.initials: T
authors.lastname: Sakai
authors.forename: K
authors.initials: K
authors.lastname: Kumano
authors.forename: M
authors.initials: M
authors.lastname: Obara
authors.forename: T
authors.initials: T
authors.lastname: Koike
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001853:Bone Marrow / Q000473:pathology; D016465:Bone Marrow Purging; D018956:CD5 Antigens; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000097:blood / Q000473:pathology / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000473:pathology / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D012074:Remission Induction; D000069283:Rituximab; D012878:Skin Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D014182:Transplantation, Autologous
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018956:CD5 Antigens; D000069283:Rituximab